W. Kast

S. H. van der Burg, W. Kast, C. Melief, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC- restricted and MHC-regulated; a model for MHC-disease associations

W. Kast, C. Melief, L. D. de Waal, 1986, The Journal of experimental medicine.

Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.

J. Drijfhout, W. Kast, P. Kenemans, 1997, Cancer letters.

Genetic Control of T-Cell and NK-Cell Protection Against Lethal Sendai Virus Infection

W. Kast, C. Melief, A. Voordouw, 1987 .

Functional and ultrastructural aspects of antigen processing by dendritic cells.

W. Kast, C. Melief, H. Geuze, 1995, Advances in experimental medicine and biology.

Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells.

W. Kast, C. Melief, H. Ploegh, 1989, Journal of immunology.

MurineCytomegalovirus Interacts withMajor Histocompatibili ty ComplexClass IMolecules ToEstablish Cellular Infection

W. Kast, G. Shellam, M. Wykes, 1993 .

Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.

S. H. van der Burg, R. Brandt, W. Kast, 1996, Journal of immunology.

Pretransplantation blood transfusion revisited.

W. Kast, C. Melief, I. T. Ten Berge, 1991, The New England journal of medicine.

T-Cell Repertoire Tuning by the MHC in Protection Against Lethal Virus Infection and in Rejection of H-Y Disparate Skin Grafts

W. Kast, C. Melief, C. Boog, 1986 .

Abolition of specific immune response defect by immunization with dendritic cells

W. Kast, C. Melief, C. Boog, 1985, Nature.

Regulation of the cytotoxic T lymphocyte response against Sendai virus analyzed with H-2 mutants.

W. Kast, C. Melief, L. D. de Waal, 1983, Journal of immunology.

Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.

W. Kast, C. Melief, 1991, Seminars in cancer biology.

Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells.

W. Kast, C. Melief, J. Bluestone, 1990, Journal of Immunology.

Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells

W. Kast, C. Melief, L. D. de Waal, 1984, The Journal of experimental medicine.

MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells.

W. Kast, C. Melief, J. Neefjes, 1995, Journal of immunology.

Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.

R. Offringa, W. Kast, C. Melief, 1998, Cancer research.

T-cell immunotherapy of cancer.

W. Kast, C. Melief, 1991, Research in immunology.

Thymic immune response gene function in radiation chimeras reconstituted with purified hemopoietic stem cells

W. Kast, C. Melief, J. Visser, 1987, European journal of immunology.

Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the Hepatitis B core antigen (HBcAg) c/e1-region

G. Dougan, W. Kast, R. Tindle, 1999, Archives of Virology.

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

L. Zitvogel, J. Mayordomo, W. Kast, 1995, Nature Medicine.

A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation.

W. Kast, C. Melief, C. Figdor, 1992, Journal of immunological methods.

Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells.

W. Kast, C. Melief, C. Boog, 1988, Journal of immunology.

Cytotoxic T lymphocytes against the antigen‐processing‐defective RMA‐S tumor cell line

W. Kast, A. Sijts, J. Nieland, 1992, European journal of immunology.

Failure and Success in Abolition of Virus‐Specific CTL‐Response Defects by Dendritic Cells

W. Kast, B. Roep, C. Melief, 1988 .

Control of Cytotoxic T-Lymphocyte Responses By Class-I and Class-II H-2 Molecules, Studied with H-2 Mutants

W. Kast, C. Melief, R. Melvold, 1983 .

Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes

S. H. van der Burg, J. Drijfhout, W. Kast, 1993, European journal of immunology.

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors

S. H. van der Burg, M. Feltkamp, W. Kast, 1995, European journal of immunology.

Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity.

M. Feltkamp, W. Kast, C. Melief, 1994, Molecular immunology.

In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes.

W. Kast, C. Melief, 1991, Immunology letters.

Peptide selection by MHC class I molecules

Hidde L. Ploegh, T. Schumacher, W. Kast, 1991, Nature.

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro

Hidde L. Ploegh, Marie-Thérèse Heemels, T. Schumacher, 1990, Cell.

Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences.

M. Feltkamp, W. Kast, C. Melief, 1995, Journal of immunology.

Human T cell responses to endogenously presented HLA‐A*0201 restricted peptides of simian virus 40 large T antigen

W. Kast, M. Carbone, M. Provenzano, 2001, Journal of cellular biochemistry.

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

G. Fleuren, R. Offringa, W. Kast, 1997, The Journal of experimental medicine.

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition

W. Kast, A. Mackensen, M. Nishimura, 2009, Cancer Immunology, Immunotherapy.

HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS.

S. H. van der Burg, J. Drijfhout, W. Kast, 1997, Journal of immunology.

Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic major histocompatibility complex antigens.

W. Kast, C. Melief, L. D. de Waal, 1990, Human immunology.

Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.

S. H. van der Burg, W. Kast, C. Melief, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor.

M. Feltkamp, W. Kast, C. Melief, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7.

M. Rudolf, W. Kast, C. Melief, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins.

A Sette, J Sidney, J. Sidney, 1994, Journal of immunology.

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.

W. Kast, C. Melief, R. Meloen, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.

A. Sette, G. Fleuren, C. Melief, 1996, Cancer research.

Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.

H. Grey, A. Sette, M. Ressing, 1995, Journal of immunology.

Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma

H. Grey, A. Sette, G. Fleuren, 2000, Journal of immunotherapy.

A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs.

J. Drijfhout, R. Brandt, W. Kast, 1995, Human immunology.

Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma

R. Offringa, J. Drijfhout, C. Melief, 1999, European journal of immunology.

Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization.

M. Feltkamp, W. Kast, C. Melief, 1995, Immunology letters.

An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301.

S. H. van der Burg, J. Drijfhout, W. Kast, 1995, Human immunology.

Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2.

J. Drijfhout, C. Melief, R. Brandt, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Differential effect of transporter Tap 2 gene introduction into RMA‐S cells on viral antigen processing

W. Kast, M. Ossevoort, F. Momburg, 1993, European journal of immunology.

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.

R. Offringa, R. Brandt, W. Kast, 1995, Journal of immunology.

Efficacy of cytotoxic T lymphocytes against virus-induced tumors.

W. Kast, C. Melief, 1990, Cancer cells.

Immunosurveillance of virus-induced tumors.

R. Offringa, W. Kast, C. Melief, 1989, Cold Spring Harbor symposia on quantitative biology.

Donor T Cells Are Responsible for the Blood Transfusion Effect Across an H-2 Class I Disparity

W. Kast, C. Melief, L. P. Waal, 1989 .

Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity.

W. Kast, C. Melief, M. Zijlstra, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors.

W. Kast, C. Melief, L. D. de Waal, 1989, Transplantation.

Peptide-based vaccines for cancer: realizing their potential

W. Kast, S. Kanodia, W. Kast, 2008, Expert review of vaccines.

Annexin A2 in Virus Infection

W. Kast, Joseph G Skeate, Julia R. Taylor, 2018, Front. Microbiol..

Lessons from T cell responses to virus induced tumours for cancer eradication in general.

W. Kast, C. Melief, 1992, Cancer surveys.

Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.

W. Kast, C. Melief, 1994, Ciba Foundation symposium.

Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes

S. H. van der Burg, J. Drijfhout, W. Kast, 1993, European journal of immunology.

Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors

W. Kast, P. Muzzio, F. Grizzi, 2006, In Vitro Cellular & Developmental Biology - Animal.

L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.

D. Lowy, W. Kast, C. Melief, 1998, Virology.